Noninvasive prenatal testing A new era of aneuploidy screening

Khushboo Srivastav, MD

Lecturer (Obstetrics and Gynecology) People's General Hospital Kathmandu, Nepal

Published Date: 2022-07-27
Visit for more related articles at Journal of Pharmaceutical Microbiology

Abstract

Since ages maternal serum marker screening (double marker, quadruple test) and the respective antenatal ultrasound imaging ( NT/NB scan and anomaly scan) have been the main stay of prenatal aneuploidy screening. Both methods, however, have large false positive rates, ranging from 2% to 7%. Since its inception in 2011, millions of pregnant women in more than 90 countries have used cell-free (cf) DNA-based Non-Invasive Prenatal Testing (NIPT) to screen for fetal chromosome abnormalities and gene mutations that cause a variety of genetic disorders. NIPT is an advance method for detecting fetal chromosomal aneuploidies that examines cell-free fetal DNA in a pregnant woman's blood. While many professional associations advocate that NIPT be used as a screening approach rather than a diagnostic test, its excellent sensitivity (true positive rate) and specificity (true negative rate) make it a compelling alternative to serum screens and invasive procedures already in use

open access journals, open access scientific research publisher, open access publisher
Select your language of interest to view the total content in your interested language

Viewing options

Flyer image

Share This Article